Full Press Release Details
("Midatech", "Company"
Posting of Circular and Notice of General
Midatech Pharma (AIM: MTPH, Nasdaq: MTP),
the R&D company focused on delivering innovative oncology and rare disease products to patients, confirms that following the
Result of Placing announcement on 4 February 2019 a circular has been posted to shareholders ahead of the General Meeting. A copy
of the circular is now available for download on the Company's website at www.midatechpharma.com.
The General Meeting will be held at 9 a.m.
on 25 February 2019 at the offices of Panmure Gordon, One New Change, London, EC4M 9AF.
For more information, please contact:
Panmure Gordon (UK) Limited (Nominated Adviser and Broker)
Corporate finance: Freddy Crossley / Emma Earl
Corporate broking: James Stearns
Consilium Strategic Communications (Financial PR)
Mary Jane Elliott / Nicholas Brown / Angela Gray
Midatech Pharma (LSE AIM: MTPH; NASDAQ:
MTP) is an R&D company focused on delivering innovative oncology and rare disease products to patients. The Company is developing
a range of improved chemotherapeutics or new immunotherapeutics, using its three proprietary platform drug delivery technologies,
all of which are in the clinic, specifically:
Each of our three technologies are thus
focussed on improved bio-delivery and bio-distribution of medicines or agents to areas of the body where they are needed and can
exert their actions in an effective, safe and precise manner.
Midatech is headquartered in Oxfordshire,
with an R&D facility in Cardiff and a manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com.